Trials / Completed
CompletedNCT04788212
Transdiagnostic Group Behavioral Activation for Autistic Adults
Adaptation of a Transdiagnostic Behavioral Activation Telehealth Group for Autistic Adults
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Rutgers, The State University of New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a telehealth Group Behavioral Activation Therapy (GBAT) for autistic adults.
Detailed description
Detailed Description: This study is being done to demonstrate the feasibility, acceptability and effectiveness of a telehealth Group Behavioral Activation Therapy (GBAT) for autistic adults. GBAT is intended to help adults manage stress, anxiety, down moods, and anger. Similar programs have been shown to be effective in other contexts but has not yet been used for autistic adults or delivered via telehealth. Because this is a new intervention, the investigators are interested in learning 1) whether GBAT can be done with autistic adults (feasibility), 2) what autistic adults think about GBAT (acceptability), and 3) whether GBAT is effective for helping autistic adults cope with their feelings. Results from this study will be used to inform adaptation to the intervention and planning for future studies to further explore its effectiveness. For this initial feasibility study, 8 autistic adults (18-40 years old) with VIQ and NVIQ\>85, reading composite at least 6th grade level and elevated symptoms of depression, anxiety or anger will be recruited.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Group Behavioral Activation Therapy for Autism Spectrum Disorder | This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults. |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2021-07-08
- Completion
- 2021-07-08
- First posted
- 2021-03-09
- Last updated
- 2021-08-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04788212. Inclusion in this directory is not an endorsement.